---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-337974"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2026-08-06T20:08:20+00:00"
generated_at: "2026-08-06T20:09:10.578280+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics Q2 2026 net loss $17.8M; cash $318.9M; Phase 3 OCEAN-1 initiated

## Summary
- Net loss of $17.8M in Q2 2026 vs $12.3M in Q2 2025; R&D expenses $15.2M (up from $9.4M).
- Cash, cash equivalents and marketable securities $318.9M; April 2026 stock offering netted $162.3M; cash runway into 2030.
- Initiated Phase 3 OCEAN-1 trial for IPF-related chronic cough; topline data expected H1 2028.
- Initiated Phase 2b LAKE trial for refractory chronic cough; sample size re-estimation expected Q4 2026.
- Submitted FDA meeting request for non-IPF ILD-related chronic cough development plan.

## SEC filing metadata
- accession: 0001193125-26-337974
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2026-08-06T20:08:20+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312526337974/0001193125-26-337974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312526337974/trvi-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-337974
- JSON: https://secwatch.observer/filing/0001193125-26-337974.json
- Plain text: https://secwatch.observer/filing/0001193125-26-337974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.